AI
BPMC

Axiom Investors’s Blueprint Medicines BPMC Stock Holding History

Axiom Investors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,676
Closed -$5.09M – 133
2025
Q2 		$5.09M Buy
39,676
+4,834
+14% +$502K 0.04% 98
2025
Q1 		$3.08M Sell
34,842
-9,062
-21% -$884K 0.03% 112
2024
Q4 		$3.83M Sell
43,904
-1,920
-4% -$176K 0.03% 114
2024
Q3 		$4.24M Sell
45,824
-4,076
-8% -$405K 0.04% 110
2024
Q2 		$5.38M Buy
49,900
+5,630
+13% +$564K 0.05% 105
2024
Q1 		$4.2M Buy
44,270
+20,288
+85% +$1.74M 0.04% 112
2023
Q4 		$2.21M Buy
+23,982
New +$1.55M 0.02% 119
2019
Q4 		– Sell
-10,439
Closed -$767K – 119
2019
Q3 		$767K Sell
10,439
-9,888
-49% -$855K 0.02% 116
2019
Q2 		$1.92M Buy
20,327
+4,130
+25% +$341K 0.05% 100
2019
Q1 		$1.3M Sell
16,197
-2,735
-14% -$202K 0.04% 113
2018
Q4 		$1.02M Sell
18,932
-969
-5% -$58.9K 0.04% 119
2018
Q3 		$1.55M Sell
19,901
-1,515
-7% -$105K 0.04% 127
2018
Q2 		$1.36M Buy
+21,416
New +$1.7M 0.04% 135

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Axiom Investors's BPMC Position: Q3 2025 in Review

Axiom Investors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 39,676 shares — an estimated $5.09M sold.

Axiom Investors first reported a position in BPMC in Q2 2018 and held it in 13 quarters. The position peaked at $5.38M in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Axiom Investors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Axiom Investors sold 39,676 Blueprint Medicines shares in Q3 2025, an estimated $5.09M.
  • Axiom Investors first reported a position in Blueprint Medicines in Q2 2018 and held it in 13 quarters.
  • Axiom Investors's Blueprint Medicines position peaked at $5.38M in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Axiom Investors's 13F filing for Q3 2025, filed 14 Nov 2025.